Streetbeat News

Price Targets

AYX

Alteryx (NYSE:AYX) has received mixed reviews from 10 analysts in the past three months, with an average 12-month price target of $45.65, up 18.57% from the previous $38.50. Ratings range from 'Buy' to 'Underweight', with recent actions including both raised and lowered price targets. Alteryx's financial performance shows a positive revenue trend but challenges in profitability, asset utilization, and debt management. The company's market capitalization is above industry average, indicating a strong market presence.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 3:00 pm

INSP

Inspire Medical Systems (NYSE:INSP) received mixed ratings from 10 financial analysts in the past three months, with a current average 12-month price target of $215.7, down 27.06% from the previous average. The company, which focuses on minimally invasive solutions for obstructive sleep apnea, has shown a 40.4% revenue growth rate as of September 30, 2023, but has a net margin of -5.57% and an ROE of -1.59%, indicating profitability challenges. Its debt-to-equity ratio is low at 0.05.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 3:00 pm

MNDY

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Monday.Com (NASDAQ:MNDY) and increased the price target from $225 to $250.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:57 pm

LBPH

Cantor Fitzgerald analyst Josh Schimmer has maintained an Overweight rating on Longboard Pharmaceuticals (LBPH) and increased the price target from $35 to $55.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:55 pm

TXT

Goldman Sachs analyst Noah Poponak has reaffirmed a Buy rating on Textron (NYSE:TXT) and maintained a price target of $98. Additionally, Textron has been added to Goldman Sachs' Conviction List, indicating a strong belief in the stock's potential.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:49 pm

PH

Goldman Sachs analyst Joe Ritchie has reaffirmed a Buy rating on Parker Hannifin (NYSE:PH) and maintained the price target of $551. Additionally, Parker Hannifin has been added to Goldman Sachs' Conviction List, indicating a strong belief in the stock's potential.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:45 pm

HUBS

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on HubSpot (NYSE:HUBS) and increased the price target from $610 to $630.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:44 pm

GLBE

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Global E Online (NASDAQ: GLBE) and increased the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:42 pm

FRSH

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Freshworks (NASDAQ:FRSH) and increased the price target from $24 to $28. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:41 pm

META

RBLX

Meta Platforms, Inc. (NASDAQ:META) has permanently reduced the price of its Quest 2 VR headset following the launch of Quest 3. The 128GB model is now $249, down from $299, and the 256GB model is $299, down from $349. Prices for various Quest 2 accessories have also been lowered. This move comes after a previous price increase in July 2022 and a reversion to the original price in June. The price cut aims to make VR more accessible and boost sales, which have been affected by shoppers' reluctance to try on headsets in stores due to hygiene concerns. Meta's VR platform includes over 500 games, with Roblox Corp (NYSE:RBLX) available on the Quest via the Meta Quest Store. META shares were down 1.31% at $349.31 in the last check.

Portfolio Pulse from Anusuya Lahiri

January 02, 2024 | 2:41 pm